UBS Group AG Has $6.75 Million Position in OPKO Health, Inc. $OPK

UBS Group AG increased its stake in OPKO Health, Inc. (NASDAQ:OPK) by 12.1% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 5,352,784 shares of the biotechnology company’s stock after purchasing an additional 577,248 shares during the quarter. UBS Group AG’s holdings in OPKO Health were worth $6,745,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Millennium Management LLC lifted its holdings in shares of OPKO Health by 39.2% during the first quarter. Millennium Management LLC now owns 6,386,911 shares of the biotechnology company’s stock worth $10,602,000 after buying an additional 1,798,385 shares during the last quarter. AQR Capital Management LLC lifted its holdings in shares of OPKO Health by 466.7% during the first quarter. AQR Capital Management LLC now owns 1,608,906 shares of the biotechnology company’s stock worth $2,671,000 after buying an additional 1,324,988 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of OPKO Health by 4.2% during the first quarter. Goldman Sachs Group Inc. now owns 4,001,214 shares of the biotechnology company’s stock worth $6,642,000 after buying an additional 161,394 shares during the last quarter. Teton Advisors LLC acquired a new position in shares of OPKO Health during the third quarter worth approximately $220,000. Finally, Cubist Systematic Strategies LLC lifted its holdings in shares of OPKO Health by 2,369.9% during the first quarter. Cubist Systematic Strategies LLC now owns 119,223 shares of the biotechnology company’s stock worth $198,000 after buying an additional 114,396 shares during the last quarter. 64.63% of the stock is currently owned by institutional investors and hedge funds.

OPKO Health Stock Performance

Shares of NASDAQ OPK opened at $1.15 on Wednesday. The business has a fifty day simple moving average of $1.16 and a 200 day simple moving average of $1.25. The company has a current ratio of 3.61, a quick ratio of 3.17 and a debt-to-equity ratio of 0.28. The firm has a market capitalization of $868.36 million, a price-to-earnings ratio of -4.26 and a beta of 1.42. OPKO Health, Inc. has a one year low of $0.98 and a one year high of $1.60.

OPKO Health (NASDAQ:OPK) last issued its earnings results on Tuesday, April 28th. The biotechnology company reported ($0.07) EPS for the quarter, meeting analysts’ consensus estimates of ($0.07). The business had revenue of $124.20 million during the quarter, compared to analyst estimates of $130.51 million. OPKO Health had a negative return on equity of 16.78% and a negative net margin of 36.63%.OPKO Health’s revenue was down 17.1% on a year-over-year basis. During the same period in the prior year, the company posted ($0.10) earnings per share. Sell-side analysts expect that OPKO Health, Inc. will post -0.29 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on OPK. Wall Street Zen lowered OPKO Health from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Weiss Ratings upgraded OPKO Health from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday. Finally, Barrington Research lowered OPKO Health from an “outperform” rating to a “market perform” rating in a research note on Wednesday, April 29th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $1.55.

OPKO Health Profile

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.